Cargando…
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)
BACKGROUND: Neoadjuvant immunotherapy targeting immune checkpoint programmed death-1 (PD-1) is under investigation in various tumour settings including non-small-cell lung cancer (NSCLC). Preclinical models demonstrate the superior power of the immunotherapy provided in a neoadjuvant (pre-operative)...
Autores principales: | Ahern, Elizabeth, Cubitt, Annette, Ballard, Emma, Teng, Michele W. L., Dougall, William C., Smyth, Mark J., Godbolt, David, Naidoo, Rishendran, Goldrick, Amanda, Hughes, Brett G. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924018/ https://www.ncbi.nlm.nih.gov/pubmed/31856909 http://dx.doi.org/10.1186/s13063-019-3951-x |
Ejemplares similares
-
Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB
por: Demchenko, Yulia N., et al.
Publicado: (2014) -
NFkB Pathway and Hodgkin Lymphoma
por: Jardin, Fabrice
Publicado: (2022) -
A critical role for the NFkB pathway in multiple myeloma
por: Demchenko, Yulia N., et al.
Publicado: (2010) -
NFkB and Nrf2 in esophageal epithelial barrier function
por: Chen, Hao, et al.
Publicado: (2013) -
Information transmission from NFkB signaling dynamics to gene expression
por: Maity, Alok, et al.
Publicado: (2020)